To The Moon

Singapore’s banking stocks, long a cornerstone of local portfolios for their resilience, dividends and regional franchise strength, faced a sharp reality check this week. Oversea-Chinese Banking Corporation (OCBC) shares tumbled 5.9% on 7 October 2026 to close at S$30.30, wiping more than S$8 billion off its market capitalisation in heavy trade. The catalyst was a Citi research note that cut the stock from Neutral to Sell with a target price of S$27.50. Peers were not spared: DBS fell 1.36% to S$77.49 and UOB dropped 2.93% to S$42.44.[]()

The sell-off comes after a strong multi-month advance that pushed DBS and OCBC to record highs in early September (and UOB to a high in July). OCBC in particular saw the sharpest re-rating among the three, with its price-to-earnings multiple expanding roughly 46% year-to-date and its dividend yield spread over Singapore 10-year bond yields compressing to a tight ~70 basis points. Citi argued that softer third-quarter expectations—flat year-on-year earnings, a projected decline in the CET1 ratio, and net interest margin pressure from higher Singapore-dollar fixed-deposit rates would derail the growth optimism that had fuelled the rally. The bank also flagged that exceptional first-half wealth-related and trading income may not fully repeat.

 Fundamentals Remain Resilient, but Expectations Have Run Ahead

Most analysts emphasise that the pullback appears driven more by profit-taking and valuation concerns than by a sudden deterioration in underlying business quality. Loan growth and wealth-management income are still viewed as supportive. Net interest margin compression is expected to moderate, while the main area of normalisation is likely non-interest income (trading, fees and insurance-related items) after an exceptionally strong second quarter.

Singapore banks continue to benefit from solid balance sheets, high capital ratios, disciplined credit costs and exposure to ASEAN trade and wealth flows. Rising or stabilising benchmark rates (including SORA) provide a potential tailwind for net interest income into 2027, according to several houses. RHB maintains an Overweight stance on the sector and names OCBC its top pick with a S$33.70 target, citing balance-sheet strength, wealth franchise momentum and relatively attractive valuation versus peers. Jefferies rates DBS a Buy (target S$91), OCBC a Hold (S$35) and UOB a Buy (S$48). Macquarie prefers UOB on valuation discount and greater sensitivity to higher Singdollar rates, followed by DBS then OCBC.

Consensus remains mixed: roughly half of covering analysts still rate OCBC a Buy, with the balance Hold or Sell. DBS is more consistently favoured for dividend visibility and capital-return programmes, while UOB trades at a clearer discount on price-to-book and price-to-earnings metrics.

Valuation After the Run-Up

The recent advance has left valuations less compelling than a year ago. DBS commands a premium for its superior return on equity (around 18%) and capital management. OCBC sits in the middle, supported by diversified income streams including insurance and wealth. UOB offers the cheapest entry point but carries higher regional asset-quality perceptions. Dividend yields, while still competitive relative to many global banks, have compressed with the price rises and now sit closer to bond yields than they did earlier in the cycle.

In short, the easy money from the 2025–2026 re-rating appears largely behind us. Further upside will depend more on sustained earnings delivery, rate trajectory and capital returns than on multiple expansion.

 Recommendations

- **Sector view**: Neutral to mildly constructive. The long-term structural case for Singapore banks—high-quality franchises, disciplined risk management, ASEAN growth exposure and reliable dividends—remains intact. Near-term, however, the stocks are more sensitive to quarterly results and rate expectations after the strong run. Prefer selective accumulation on weakness rather than aggressive buying at recent highs.

- **OCBC**: Hold / Reduce on strength. The Citi downgrade highlights legitimate risks around Q3 normalisation and stretched relative valuation. Investors already overweight may take partial profits; new money is better deployed only on further dips toward the mid-to-high S$20s, where the risk-reward improves. Longer-term holders can retain core positions for the wealth and insurance franchise.

- **DBS**: Buy on dips / Core holding. Best-in-class ROE, strong capital generation and visible dividend (including potential special returns) support a premium. Preferred for income-oriented and quality-focused investors.

- **UOB**: Buy / Accumulate. Most attractive valuation among the three and greater leverage to higher Singdollar rates. Suitable for investors willing to accept slightly higher perceived regional risk in exchange for upside potential.

**Overall portfolio stance**: Maintain Singapore banks as a core allocation within a diversified equity portfolio, but rebalance toward DBS and UOB if OCBC remains relatively expensive. Monitor third-quarter results closely for confirmation of earnings resilience and any guidance on net interest margins and capital returns. Geopolitical and rate volatility remain key external risks.

Singapore banks are not broken; they have simply become more expensive after a successful run. Selective, disciplined buying on pullbacks still makes sense for long-term investors seeking quality and income.